Eisai Enters Agreement With Minophagen; Gains Asian Access to Liver Disease Products
This article was originally published in PharmAsia News
Executive Summary
Under the shadow of Eisai's recent, massive "Dramatic Leap Plan" acquisitions, the company acquires the Asian development and marketing rights for Minophagen Pharmaceutical's Stronger Neo-Minophagen C and Glycyron products